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MyoD Meets Its Maker Minireview
Alan Rawls and Eric N. Olson domains, the sclerotome, myotome, and dermomyo-
tome. Initially, the ventral region of the somite acquiresDepartment of Molecular Biology and Oncology
The University of Texas Southwestern Medical Center a mesenchymal phenotype and forms the sclerotome,
from which the ribs and vertebrae and derived. The dor-at Dallas
6000 Harry Hines Boulevard sal half of the somite forms an epithelial sheet known
as the dermomyotome. Cells from the anterior medialDallas, Texas 75225-9149
edge of the dermomyotome adjacent to the neural tube
invaginate to form the centrally located myotomal com-
partment of the somite. The dorsomedial half of theThe discovery of the four myogenic basic helix-loop-
helix (bHLH) transcription factors MyoD, myogenin, myotome gives rise to the back (epaxial) muscles, while
cells from the ventrolateral portion migrate ventrally toMyf-5, and MRF4, each of which can activate the pro-
gram for skeletal muscle differentiation, has led to rapid form the body wall (hypaxial) muscles. At the limb levels,
cells from the ventrolateral edge of the dermomyotomeprogress toward understanding the molecular mecha-
nisms that regulate muscle gene expression (Molkentin migrate to the limb buds to form the limb musculature.
The muscles of the head and neck are thought to beand Olson, 1996). However, what regulates the myo-
genic bHLH genes to initiate the pathway for skeletal derived from paraxial mesoderm anterior to the somites
and from prechordal mesoderm.muscle development is a question that has continued
to loom large in the field. In moving upstream in a regula- Cells from the newly formed somite are initially
multipotent and become committed to specific fates intory pathway for cell type specificity, there must ulti-
mately be non±cell type±specific factors that trigger response to instructive signals from surrounding cell
types (Yun and Wold, 1996). Wnts, which are producedcommitment to a particular lineage. The myogenic bHLH
factors are the earliest markers specific for the skeletal by the dorsal neural tube and surface ectoderm, induce
dermomyotome-specific gene expression, whereasmuscle lineage in vertebrate embryos, but whether their
expression signals the initiation of this developmental sonic hedgehog (Shh), secreted from the notochord and
ventral floorplate of the neural tube, induces sclero-pathway or is preceded by an even earlier muscle-spe-
cific factor has not been previously determined. Two tome-specific gene expression, thereby excluding myo-
genic cells from this region of the somite. Expressionpapers in this issue of Cell begin to clarify these matters:
using complementary approaches, the Buckingham and of myogenic genes in the myotome requires a combina-
tion of Wnts and Shh. In addition, an inhibitory signalLassar labs (Tajbakhsh et al., 1997; Maroto et al., 1997
[both in this issue of Cell]) demonstrate that the paired- (probably bone morphogenetic protein 4) produced by
the lateral mesoderm prevents myogenesis. Thus, over-type homeobox gene Pax-3 is a key regulator of skeletal
muscle development that is both necessary and suffi- lapping gradients of multiple signaling molecules result
in specific patterns of gene expression throughout thecient (in certain cellular contexts) to activate MyoD ex-
pression and initiate the myogenic program in vivo and developing somite. How these signaling molecules acti-
vate the myogenic pathway (or any other somitic path-in vitro. Since Pax-3 is expressed in a wide range of cell
types, it must act through combinatorial mechanisms way) is unknown, but the regulatory genes that specify
the identity of the myogenic lineage must be exquisitelyto control commitment to the myogenic lineage. Indeed,
there is evidence suggesting the existence of positive sensitive to the concentrations of these secreted factors
because myogenesis occurs in only a narrowly definedand negative regulators that dictate a cell's respon-
siveness to the myogenic functions of Pax-3. subset of somitic cells.
In the mouse, Myf-5 is the first of the myogenic bHLHIt Starts in the Somites
In vertebrates, all skeletal muscles with the exception of genes to be expressed, with transcripts appearing in
myogenic precursor cells at the dorsomedial edge of thea few muscles in the head are derived from the somites,
which form as transient epithelial spheres within the dermomyotome as they invaginate to form the myotome
(Yun and Wold, 1996). Myogenin is expressed soonparaxial mesoderm flanking the neural tube (Christ and
Ordahl, 1995) (Figure 1). As the somites mature, they thereafter, as myotomal cells begin to differentiate, and
MyoD and MRF4 are expressed a day or two later. Cellsbecome compartmentalized into three distinct cellular
Figure 1. Domains of Gene Expression in the
Somites
A schematic diagram of a transverse section
through the neural tube and differentiated
somites is shown. Domains of expression of
various regulatory genes are indicated. ec,
surface ectoderm; lb, limb bud; der, dermo-
myotome; my, myotome; scl, sclerotome; nt,
neural tube; no, notochord.
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that migrate from the dermomyotome to the limb bud c-Met, which binds the migratory peptide growth factor,
are committed to a myogenic fate, but they do not ex- scatter factor (Bladt et al., 1995). The absence of c-Met
press the myogenic bHLH genes until they reach their expression in splotch mice suggests that c-met is a
destination, at which time these regulatory genes are likely target gene for Pax-3 and that the lack of c-Met
switched on and myogenesis ensues. How these migra- signaling accounts for the inability of splotch myoblasts
tory cells maintain their commitment to a myogenic fate to migrate (Yang et al., 1996).
in the absence of myogenic bHLH gene expression has In the paper from Buckingham's group (Tajbakhsh et
been a mystery. al., 1997), Pax-3 and Myf-5 mutations were combined by
A Pathway of Myogenic bHLH Genes intercrossing the two mutant lines of mice. Remarkably,
The phenotypes (or lack thereof) of mice lacking the mice lacking both genes developed virtually no skeletal
myogenic bHLH genes have provided a framework for muscle in the trunk and failed to express MyoD in this
thinking about the roles of these genes in specification region of the embryo. Since MyoD is expressed in trunk
and differentiation of the skeletal muscle lineage. Mice muscle precursors of Myf-5-null embryos, its failure to
lacking either MyoD or Myf-5 form skeletal muscle that be expressed in Myf-5/Pax-3 double mutants reveals an
is essentially normal, whereas mice lacking both genes essential role for Pax-3 as a regulator of MyoD expres-
are devoid of skeletal muscle cells and show no expres- sion. Thus, in addition to its role in regulating migration
sion of molecularmarkers of the skeletal muscle lineage, of limb muscle precursors, Pax-3 also appears to act
supporting the notion that these genes act at an early like Myf-5 to control MyoD expression and specification
step in the lineage to specify myoblast identity (Rudnicki of trunk muscles. To further distinguish the roles of
et al., 1993). The apparent ability of either MyoD or Myf-5 Pax-3 in specificationand migration of limb and hypaxial
to support muscle development in the absence of the muscle precursors it will be interesting to compare the
other has been interpreted to indicate either that the phenotypes of Myf-5/Pax-3 mutants with Myf-5/c-met
two genes have redundant functions in the same cells, mutant mice.
or that there are separate myogenic lineages, one de- Muscles of the head are essentially unaffected by the
pendent on MyoD, the other on Myf-5; in the absence combined Pax-3/Myf-5 mutations. Since these muscles,
of one lineage, the other would expand to compensate. like those in the body, are completely absent in MyoD/
In myogenin-null mice, MyoD and Myf-5 are expressed Myf-5 double mutants and are therefore dependent on
and myoblasts are properly specified and positioned,
the compensatory pathways controlled by these myo-
but there is a block in differentiation. Myogenin therefore
genic bHLH genes, MyoD expression in the head muscle
appears to lie in a geneticpathway downstream of MyoD
lineage must be Pax-3-independent. Consistent with
and Myf-5 and to have a unique role in activating the
this notion, neither Pax-3 nor Pax-7 is expressed in head
program for muscle cell differentiation (Molkentin and
muscle precursors.
Olson, 1996).
An important question that arises from these resultsNecessity of Pax-3 for Muscle Development
is whether MyoD expression is completely independentSeveral members of the Pax family of homeobox genes
of Myf-5 or whether there may also be a Myf-5-mediatedare expressed in distinct domains within developing so-
pathway for MyoD activation. On this issue, there ismites. Pax-3 and Pax-7 are expressed in the paraxial
disagreement. Tajbakhsh et al. (1997) show that MyoDmesoderm prior to somitogenesis and in the dorsal
expression is delayed in most but not all of the trunkhalves of epithelial somites before becoming restricted
somites of Myf-5 mutant embryos, which they interpretto the ventrolateral and dorsomedial domains, respec-
to indicate that the initial activation of MyoD is depen-tively, of the dermomyotome (Goulding et al., 1991;
dent on Myf-5 and that Pax-3 regulates MyoD expres-Jostes et al., 1991). Both Pax-3 and Pax-7 are excluded
sion later. This conclusion is supported by their observa-from the myotome. Pax-3 is also expressed in the migra-
tion that Myf-5 and MyoD are expressed in the sametory population of myogenic precursors that enters the
myotomal muscle cells of normal embryos. However,limb buds from the dermomyotome and is down-regu-
these conclusions differ from those of previous studieslated as these cells begin to differentiate and express
which concluded that MyoD was activated on time inMyoD and Myf-5. In addition to their expression in para-
Myf-5 mutant embryos and that the expression of MyoDxial mesoderm, Pax-3 and Pax-7 are expressed at high
and Myf-5 was mutually exclusive at the cellular levellevels in the dorsal neural tube.
in vivo and in embryonic stem cells in vitro (Braun andThe first indication of a role for Pax-3 in muscle devel-
Arnold, 1996). This discrepancy may be reconciled ifopment came from the phenotype of the splotch mouse
MyoD expression is dependent on Myf-5 in some musclemutant, which lacks a functional Pax-3 gene, and is
cell types and independent in others.devoid of limb muscles (Bober et al., 1994). Muscles of
How important is the Pax-3-dependent pathway forthe back and body wall are unaffected in splotch mice,
MyoD expression during skeletal muscle development?consistent with their origin from a separate muscle lin-
The simplest interpretation is that this pathway can beeage from the limb musculature. If the lateral halves of
almost entirely compensated for by Myf-5. That MyoDsomites derived from splotch mice are transplanted into
is expressed in the myotomal muscle lineage of Pax-3the limb buds of chick embryos, the mutant mouse myo-
mutant mice indicates that there must be a Pax-3-inde-blasts are able to differentiate (Daston et al., 1996). This
pendent pathway for MyoD gene activation and Myf-5suggests that the muscle deficiency in splotch mice
would seem to be the likely regulator of MyoD in thisresults from a failure of muscle precursors to invade the
situation. Conversely, in the Myf-5-mutant mouse, thelimb, rather than an inability of myoblasts to differenti-
Pax-3-dependent pathway can apparently support nor-ate. The limb muscle phenotype of splotch mice is simi-
lar to that of mice lacking the tyrosine kinase receptor mal muscle development. It is unlikely that Pax-7 can
Minireview
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substitute for Pax-3 to support MyoD expression, since neurogenic program is extinguished in neural cells that
are converted to a myogenic fate also has not yet beenPax-7 continues to be expressed in Pax-3/MyfÐ5 dou-
ble mutants in which MyoD fails to be expressed. The examined.
Surprisingly, Pax-3 was unable to induce myogenesisphenotype of Pax-7/Myf-5mutant mice will be of interest
in this regard. It is also important to keep in mind that in the 10T1/2 mouse fibroblast-like cell line, which is
readily converted to muscle by MyoD and was originallyPax-3 and MyoD are expressed in mutually exclusive
patterns in the somite and lateral muscle lineage, sug- used to characterize the myogenic activity of MyoD. In
fact, forced expression of Pax-3 in 10T1/2 cells blocksgesting that Pax-3 is likely to be involved in activation,
but not in maintenance of MyoD expression. their ability to induce muscle genes in response to MyoD
and in the C2 muscle cell line, Pax-3 blocks differentia-Sufficiency of Pax-3 for Myogenesis
The study from Tajbakhsh et al. (1997) indicates that tion (Epstein et al., 1995). Thus, the factors required for
muscle gene activation by MyoD must be distinct fromPax-3 is necessary for normal myogenesis in vivo and
that it regulates (directly or indirectly) MyoD expression; those required by Pax-3. Moreover, in a subset of alveo-
lar rhabdomyosarcomas, chromosomal translocationbut is Pax-3 sufficient to activate the myogenic pro-
gram? The answer seems to be yes, sometimes. In the results in fusion of the amino-terminal DNA binding do-
main of Pax-3 to the C-terminal transcription activationstudy by Maroto et al. (1997), Pax-3 was expressed
ectopically in a variety of nonmuscle cell types and was domain of the forkhead transcription factor FKHR, re-
sulting in the creation of a novel transcription factor thatfound, under some conditions, to activate MyoD expres-
sion and myogenic differentiation. prevents myogenesis (Barr et al., 1993).
Cell Background Determines Myogenic PotentialAn initial clue that Pax-3 (and possibly Pax-7) might
be an activator of MyoD expression came from experi- The ability of Pax-3 to activate myogenesis in some cell
types and inhibit it in others dramatizes the importancements in which explants of chick paraxial mesoderm
were assayed for their ability to activate myogenesis in of cell background in dictating transcriptional respon-
siveness of muscle genes. The simplest explanation forresponse to Wnts, Shh, and ectoderm. Activation of
MyoD expression under these conditions was preceded this specificity in responsiveness is the existence of
unique combinations of positive and negative regulatoryby expression of Pax-3 and Pax-7, as well as Myf-5.
Using a retroviral expression system,Maroto et al. (1997) factors in different cell types that influence the myogenic
functions of Pax-3.went on to show that forced expression of Pax-3 was
sufficient to induce expression of myogenic bHLH genes The finding that retroviral-mediated expression of
Pax-3 can induce myogenesis indissociated neural tubeand muscle differentiation markers in cultured paraxial
mesoderm and to a lesser extent in dermal fibroblasts. cells, even though these cells normally express Pax-3,
suggests that elevating Pax-3 expression above aLateral mesoderm, which normally acts as a source of
signals that inhibit myogenesis, was also induced to threshold can trigger the myogenic program. The inter-
pretation favored by Maroto et al. (1997) is that theexpress MyoD and downstream markers of myogenesis
in response to ectopic Pax-3 expression. Perhaps most myogenic functions of Pax-3 are normally suppressed
by an inhibitor in the neural tube and that exceeding thesurprising was the finding that muscle gene expression
could be inducedby forced expression of Pax-3 indisso- inhibitory activity of this factor with excess Pax-3 can
result in myogenesis. This model assumes that potentialciated neural tube cells. These experiments were only
performed in vitro; it remains to be determined whether cofactors required by Pax-3 to initiate myogenesis are
expressed in the neural tube. Potential inhibitors ofhigh levels of Pax-3 can also induce myogenesis in neu-
ral tube cells in the embryo. Whether the endogenous Pax-3 activity in the neural tube would presumably also
Figure 2. A Model for Regulatory Interactions
in the Myogenic Pathway
Wnts and Shh produced by the neural tube
and notochord, respectively, cooperate to in-
duce Myf-5 and Pax-3 expression in the so-
mites. Surface ectoderm also induces Myf-5
and MyoD expression. Myf-5 appears to reg-
ulate the early expression and Pax-3 the late
expression of MyoD. Pax-3 also regulates
c-Met expression, which is required for mi-
gration of muscle precursor cells to the limb
bud. Myogenin acts downstream of MyoD
and Myf-5 and is an essential activator of
myogenesis in lateral and medial muscle lin-
eages.
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intermediate steps? MyoD transcriptionhas been shown
to be controlled by two distal upstream enhancers (Gol-
dhammer et al., 1992; Asakura et al., 1995). A simple
model would be that Pax-3 binds directly to one of these
enhancers and activates MyoD transcription in collabo-
ration with other enhancer-binding factors. However,
since MyoD is expressed in only a subset of cells that
express Pax-3, there must be other positive and nega-
tive cofactors that modulate the myogenic activity of
Pax-3. What are the identities of such factors and what
are their mechanisms of action? Pax-3 also has other
functions in addition to regulating MyoD expression.
What determines the sets of downstream genes regu-
lated by Pax-3 in different cell types?
While there has been headway toward unraveling the
mechanisms that regulate MyoD expression, little is
known about the regulation of Myf-5. Does Pax-3 also
play a role in Myf-5 regulation and what are the regula-
tory factors that control MyoD and Myf-5 expression in
head muscle lineages? Moreover, what is the logic be-
hind the existence of multiple apparently separate path-
ways for the formation of skeletal muscle when a single
pathway would seem sufficient? Does this complexity
simply expand the regulatory potential within these lin-
eages or is there another reason? In this regard, what
is the mechanism that allows one myogenic lineage to
compensate for another or one genetic pathway to take
over when another is absent?
Finally, MyoD has been widely heralded as a ªmaster
regulatorº of the myogenic lineage. A lesson from these
studies is that being a master or a slave depends on
the point of view.
